Aclaris Therapeutics Company Profile (NASDAQ:ACRS)

About Aclaris Therapeutics

Aclaris Therapeutics logoAclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACRS
  • CUSIP:
Key Metrics:
  • Previous Close: $29.52
  • 50 Day Moving Average: $27.47
  • 200 Day Moving Average: $25.14
  • 52-Week Range: $14.12 - $31.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.17
  • P/E Growth: -0.21
  • Market Cap: $660.11M
  • Outstanding Shares: 21,432,000
  • Beta: 2.19
Profitability:
  • Return on Equity: -47.62%
  • Return on Assets: -45.47%
Debt:
  • Current Ratio: 18.65%
  • Quick Ratio: 18.65%
Additional Links:
Companies Related to Aclaris Therapeutics:

Analyst Ratings

Consensus Ratings for Aclaris Therapeutics (NASDAQ:ACRS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.50 (5.52% upside)

Analysts' Ratings History for Aclaris Therapeutics (NASDAQ:ACRS)
Show:
DateFirmActionRatingPrice TargetDetails
11/29/2016Leerink SwannInitiated CoverageOutperformView Rating Details
11/18/2016Jefferies Group LLCReiterated RatingBuy$29.00 -> $32.00View Rating Details
9/30/2016JMP SecuritiesInitiated CoverageOutperform$34.00View Rating Details
6/10/2016GuggenheimInitiated CoverageBuy$35.00View Rating Details
3/16/2016Citigroup Inc.Lower Price TargetBuy$34.00 -> $29.00View Rating Details
11/2/2015William BlairInitiated CoverageOutperform$30.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2017        
11/3/2016Q3($0.66)($0.50)ViewListenView Earnings Details
8/11/2016Q2($0.61)($0.62)ViewListenView Earnings Details
5/11/2016Q1($0.50)($0.65)ViewListenView Earnings Details
3/23/2016Q4($0.40)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aclaris Therapeutics (NASDAQ:ACRS)
Current Year EPS Consensus Estimate: $-2.36 EPS
Next Year EPS Consensus Estimate: $-3.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.54)($0.54)($0.54)
Q3 20161($0.69)($0.69)($0.69)
Q4 20162($0.78)($0.50)($0.64)
Q1 20171($0.54)($0.54)($0.54)
Q2 20171($0.59)($0.59)($0.59)
Q3 20171($0.80)($0.80)($0.80)
Q4 20171($1.04)($1.04)($1.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aclaris Therapeutics (NASDAQ:ACRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aclaris Therapeutics (NASDAQ:ACRS)
Insider Ownership Percentage: 46.40%
Institutional Ownership Percentage: 61.94%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/10/2017Anand MehraDirectorSell750,000$28.25$21,187,500.00View SEC Filing  
11/18/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell907,828$23.03$20,907,278.84View SEC Filing  
10/26/2016Kamil Ali-JacksonInsiderSell3,912$21.83$85,398.96View SEC Filing  
9/28/2016Kamil Ali-JacksonInsiderSell1,841$24.66$45,399.06View SEC Filing  
9/16/2016Ra Capital Management, LlcMajor ShareholderSell525,550$24.19$12,713,054.50View SEC Filing  
8/26/2016Kamil Ali-JacksonInsiderSell3,738$20.35$76,068.30View SEC Filing  
2/23/2016Ra Capital Management, LlcMajor ShareholderBuy39,726$17.15$681,300.90View SEC Filing  
1/20/2016Ra Capital Management, LlcMajor ShareholderBuy7,803$19.87$155,045.61View SEC Filing  
1/13/2016Ra Capital Management, LlcMajor ShareholderBuy15,637$19.10$298,666.70View SEC Filing  
10/29/2015Ra Capital Management, LlcMajor ShareholderBuy244,200$14.00$3,418,800.00View SEC Filing  
10/22/2015Ra Capital Management, LlcMajor ShareholderBuy5,410$14.03$75,902.30View SEC Filing  
10/21/2015Ra Capital Management, LlcMajor ShareholderBuy34,999$14.89$521,135.11View SEC Filing  
10/14/2015Ra Capital Management, LlcMajor ShareholderBuy42,813$14.06$601,950.78View SEC Filing  
10/13/2015Albert ChaDirectorBuy454,545$11.00$4,999,995.00View SEC Filing  
10/13/2015Fmr LlcInsiderBuy335,455$11.00$3,690,005.00View SEC Filing  
10/13/2015Sofinnova Venture Partners ViiMajor ShareholderBuy409,090$11.00$4,499,990.00View SEC Filing  
10/8/2015Ra Capital Management, LlcMajor ShareholderBuy2,237,130$10.86$24,295,231.80View SEC Filing  
10/7/2015Vivo Ventures Vii, LlcMajor ShareholderBuy13,352$11.00$146,872.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aclaris Therapeutics (NASDAQ:ACRS)
DateHeadline
finance.yahoo.com logoAclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5% (NASDAQ:ACRS)
finance.yahoo.com - February 24 at 9:32 AM
finance.yahoo.com logoAclaris Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 (NASDAQ:ACRS)
finance.yahoo.com - February 23 at 3:19 PM
thestreet.com logoSkin Lesion Drug Only Scratches the Surface, Says Aclaris CEO (NASDAQ:ACRS)
www.thestreet.com - February 6 at 3:22 PM
nasdaq.com logoNoteworthy Thursday Option Activity: P, ACRS, EW (NASDAQ:ACRS)
www.nasdaq.com - February 2 at 8:21 PM
finance.yahoo.com logoAclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors (NASDAQ:ACRS)
finance.yahoo.com - January 26 at 3:33 PM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure (NASDAQ:ACRS)
biz.yahoo.com - January 26 at 3:33 PM
News IconNDX Reaches Over Five Thousand Today (NASDAQ:ACRS)
www.fxstreet.com - January 10 at 1:37 AM
finance.yahoo.com logoWhy Aclaris Therapeutics (ACRS) Stock Might be a Great Pick (NASDAQ:ACRS)
finance.yahoo.com - January 3 at 3:31 PM
finance.yahoo.com logoAclaris to Present at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:ACRS)
finance.yahoo.com - January 3 at 8:18 AM
News IconAimmune Therapeutics, Inc. (NASDAQ:AIMT) Broker Price Targets For The Coming Week (NASDAQ:ACRS)
www.perspectivabetica.com - December 16 at 8:30 PM
News IconAre Major Holders Truncating Their Positions in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) (NASDAQ:ACRS)
canalcncarauca.com - December 16 at 8:30 PM
insidermonkey.com logoAclaris Therapeutics Inc (ACRS) Hedge Funds Are Snapping Up (NASDAQ:ACRS)
www.insidermonkey.com - December 9 at 3:23 PM
investingnews.com logoAclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001 for the Treatment of Alopecia Totalis and Alopecia Universalis (NASDAQ:ACRS)
investingnews.com - December 8 at 1:28 AM
finance.yahoo.com logoAclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, … (NASDAQ:ACRS)
finance.yahoo.com - December 8 at 1:28 AM
streetinsider.com logoAclaris Therapeutics (ACRS) Commences ATI-50001 Phase 1 (NASDAQ:ACRS)
www.streetinsider.com - December 8 at 1:28 AM
us.rd.yahoo.com logoAclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis (NASDAQ:ACRS)
us.rd.yahoo.com - December 7 at 3:20 PM
us.rd.yahoo.com logo8:21 am Aclaris Therapeutics initiates phase 1 clinical trial for ATI-50001 for the treatment of alopecia totalis and alopecia universalis (NASDAQ:ACRS)
us.rd.yahoo.com - December 7 at 3:20 PM
zacks.com logoWhy Aclaris (ACRS) Could Be Positioned for a Surge (NASDAQ:ACRS)
www.zacks.com - December 2 at 10:53 AM
capitalcube.com logoAclaris Therapeutics, Inc. :ACRS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:ACRS)
us.rd.yahoo.com - November 30 at 10:22 AM
us.rd.yahoo.com logoEdited Transcript of ACRS earnings conference call or presentation 3-Nov-16 12:30pm GMT (NASDAQ:ACRS)
us.rd.yahoo.com - November 30 at 10:22 AM
us.rd.yahoo.com logoCoverage initiated on Aclaris Therapeutics by Leerink Partners (NASDAQ:ACRS)
us.rd.yahoo.com - November 30 at 10:22 AM
finance.yahoo.com logoAclaris Therapeutics (ACRS) Worth Watching: Stock Up 7.5% (NASDAQ:ACRS)
finance.yahoo.com - November 30 at 10:22 AM
finance.yahoo.com logoAclaris Therapeutics to Attend Upcoming Investor Conferences (NASDAQ:ACRS)
finance.yahoo.com - November 22 at 1:30 PM
finance.yahoo.com logoAclaris Files for Secondary Offering (NASDAQ:ACRS)
finance.yahoo.com - November 19 at 8:24 PM
4-traders.com logoAclaris Therapeutics : Announces Pricing of Public Offering of Common Stock (NASDAQ:ACRS)
www.4-traders.com - November 19 at 3:17 PM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St (NASDAQ:ACRS)
biz.yahoo.com - November 18 at 8:58 PM
bizjournals.com logoPharma company targeting skin disorders plans $91M stock sale (NASDAQ:ACRS)
www.bizjournals.com - November 18 at 3:19 PM
finance.yahoo.com logoAclaris Announces Pricing of Public Offering of Common Stock (NASDAQ:ACRS)
finance.yahoo.com - November 17 at 8:34 PM
fool.com logoWhy Aclaris Therapeutics, Inc. Stock Is Down Today (NASDAQ:ACRS)
www.fool.com - November 17 at 1:34 PM
4-traders.com logoAclaris Therapeutics : Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition (NASDAQ:ACRS)
www.4-traders.com - November 16 at 3:20 PM
benzinga.com logoA-101 (NASDAQ:ACRS)
www.benzinga.com - November 16 at 12:41 PM
rttnews.com logoAll Is Well With ACRS, First Avastin Biosimilar In The Works, CLRB Abuzz (NASDAQ:ACRS)
www.rttnews.com - November 16 at 12:41 PM
biz.yahoo.com logoAclaris Therapeutics Inc Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis Call scheduled for 5:00 pm ET today (NASDAQ:ACRS)
biz.yahoo.com - November 16 at 12:41 PM
finanznachrichten.de logoACLARIS THERAPEUTICS INC (NASDAQ:ACRS)
www.finanznachrichten.de - November 15 at 9:31 PM
finance.yahoo.com logoAclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition (NASDAQ:ACRS)
finance.yahoo.com - November 15 at 9:31 PM
streetinsider.com logoAclaris Therapeutics (ACRS) Announces Two A-101 Phase 3s Met All Primary, Secondary Endpoints as SK Treatment (NASDAQ:ACRS)
www.streetinsider.com - November 15 at 9:31 PM
finance.yahoo.com logoACLARIS THERAPEUTICS, INC. Financials (NASDAQ:ACRS)
finance.yahoo.com - November 9 at 3:21 PM
cnbc.com logoAclaris reports 3Q loss (NASDAQ:ACRS)
www.cnbc.com - November 3 at 12:59 PM
einnews.com logoAclaris Therapeutics Reports Third Quarter 2016 Financial Results (NASDAQ:ACRS)
brazilbusiness.einnews.com - November 3 at 12:59 PM
bizjournals.com logoMalvern pharma firm wants to begin human testing of hair loss disease treatment (NASDAQ:ACRS)
www.bizjournals.com - November 3 at 12:59 PM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E (NASDAQ:ACRS)
biz.yahoo.com - November 2 at 9:14 PM
einnews.com logoSingapore starts trial of ex-banker linked to 1MDB Fund (NASDAQ:ACRS)
uspolitics.einnews.com - October 31 at 9:14 AM
finance.yahoo.com logoAclaris Therapeutics Submits Investigational New Drug Application for ATI-50001 to Treat Alopecia Universalis and Alopecia Totalis (NASDAQ:ACRS)
finance.yahoo.com - October 31 at 9:14 AM
4-traders.com logoAclaris Therapeutics : Honored as One of the Best Places to Work in Pennsylvania (NASDAQ:ACRS)
www.4-traders.com - October 29 at 11:36 AM
finance.yahoo.com logoAclaris Therapeutics Honored as One of the Best Places to Work in Pennsylvania (NASDAQ:ACRS)
finance.yahoo.com - October 28 at 12:56 PM
finance.yahoo.com logoAclaris Therapeutics to Announce Third Quarter 2016 Financial Results on November 3, 2016 (NASDAQ:ACRS)
finance.yahoo.com - October 25 at 8:07 AM
finance.yahoo.com logoNew Observational Study Demonstrates Patient Impact of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans (NASDAQ:ACRS)
finance.yahoo.com - October 19 at 3:31 PM
insidermonkey.com logoAclaris Therapeutics Inc (ACRS): RA Capital Management Disposes of 1.1 Million Shares (NASDAQ:ACRS)
www.insidermonkey.com - October 7 at 3:16 PM
News IconAclaris Therapeutics - Chart Of The Day (NASDAQ:ACRS)
www.talkmarkets.com - October 4 at 8:03 AM
streetinsider.com logoForm 424B3 Aclaris Therapeutics, (NASDAQ:ACRS)
www.streetinsider.com - September 13 at 3:17 PM

Social

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Where is Aclaris Therapeutics' stock going? Where will Aclaris Therapeutics' stock price be in 2017?

5 analysts have issued 12 month price objectives for Aclaris Therapeutics' stock. Their forecasts range from $29.00 to $35.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $32.50 in the next twelve months.

When will Aclaris Therapeutics announce their earnings?

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 21st 2017.

Who owns Aclaris Therapeutics stock?

Aclaris Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (15.32%), Franklin Resources Inc. (7.13%), Perceptive Advisors LLC (5.88%), FMR LLC (2.19%), Marshall Wace LLP (2.18%) and FIL Ltd (2.03%). Company insiders that own Aclaris Therapeutics stock include Albert Cha, Anand Mehra, Fmr Llc, Kamil Ali-Jackson, Ra Capital Management, Llc, Sofinnova Venture Partners Vii, Ventures Fund Vii LP Vivo and Vivo Ventures Vii, Llc.

Who sold Aclaris Therapeutics stock? Who is selling Aclaris Therapeutics stock?

Aclaris Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Vivo Capital LLC, FIL Ltd and Franklin Resources Inc.. Company insiders that have sold Aclaris Therapeutics stock in the last year include Anand Mehra, Kamil Ali-Jackson, Ra Capital Management, Llc and Ventures Fund Vii LP Vivo.

Who bought Aclaris Therapeutics stock? Who is buying Aclaris Therapeutics stock?

Aclaris Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, EcoR1 Capital LLC, Acuta Capital Partners LLC, Marshall Wace LLP, Deerfield Management Co., Renaissance Technologies LLC, Foresite Capital Management III LLC and Alyeska Investment Group L.P.. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Albert Cha, Fmr Llc, Ra Capital Management, Llc, Sofinnova Venture Partners Vii and Vivo Ventures Vii, Llc.

How do I buy Aclaris Therapeutics stock?

Shares of Aclaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aclaris Therapeutics stock cost?

One share of Aclaris Therapeutics stock can currently be purchased for approximately $30.80.

Aclaris Therapeutics (NASDAQ:ACRS) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Earnings History Chart

Earnings by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Dividend History Chart

Dividend Payments by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Last Updated on 2/25/2017 by MarketBeat.com Staff